BiotechTube

Sapropterin (Kuvan)

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Jul 1, 2008 → May 1, 2018

NCT ID
NCT00730080

About Sapropterin (Kuvan)

Sapropterin (Kuvan) is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT00730080. Target conditions include Phenylketonuria.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00730080Pre-clinicalCompleted

Competing Products

20 competing products in Phenylketonuria

See all competitors
ProductCompanyStageHype Score
SYNB1934v1 + PlaceboSynlogicPhase 3
69
SYNB1618 + PlaceboSynlogicPhase 1/2
33
SYNB1618 + SYNB1934SynlogicPhase 2
44
Kuvan®MerckPhase 3
77
Kuvan®MerckApproved
85
SAR444836SanofiPhase 1/2
40
KuvanBioMarin PharmaceuticalPre-clinical
20
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
49
BMN 307BioMarin PharmaceuticalPhase 1/2
38
SapropterinBioMarin PharmaceuticalPre-clinical
20
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
74
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
74
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
74
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
82
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
49

Other Products from BioMarin Pharmaceutical

NaglazymeApproved
82
saproterin dihydrochlorideApproved
82
Pegvaliase + MethotrexateApproved
82
Kuvan®Approved
82
KuvanApproved
82